会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 52. 发明授权
    • Zero looseness fastener for a linkage assembly
    • 用于连杆组件的零松动紧固件
    • US6007039A
    • 1999-12-28
    • US151569
    • 1998-09-11
    • Nils O. OlssonGregory David Collins
    • Nils O. OlssonGregory David Collins
    • B60N2/04B60N2/02F16C11/04F16M13/00
    • B60N2/0232
    • The present invention relates generally to a fastener used for connecting a first link member to a second link member in a linkage assembly. The second link member includes a pair of aligned apertures and a slot located transversely between the apertures. The first link member includes an aperture at a first end that is designed to be received in the slot located in the second link member. The fastener has a centering post at a distal end and a head portion at a proximal end with a self-tapping portion located between the head portion and the centering post. The aperture in the first link member is aligned with the apertures in the second link member and the fastener is inserted through the apertures until the self-tapping portion contacts the first link member. Thereafter, rotation of the fastener in a first direction taps the self-tapping portion of the fastener through the aperture in the first link member. The fastener is rotated until the first link member is flush against the head portion of the fastener. Thus, the fastener rotatably secures the first link member to the second link member and prevents lateral free play movement between the fastener and the second link member, and between the first link member and the second link member.
    • 本发明一般涉及一种用于将第一连杆构件连接到连杆组件中的第二连杆构件的紧固件。 第二连杆构件包括一对对齐的孔和横向位于孔之间的槽。 第一连杆构件包括在第一端处的孔,其被设计成容纳在位于第二连杆构件中的槽中。 紧固件在远端具有定心柱,在近端具有位于头部和定心柱之间的自攻螺纹部分的头部。 第一连杆构件中的孔与第二连杆构件中的孔对准,并且紧固件穿过孔插入,直到自动攻丝部分接触第一连杆构件。 此后,紧固件在第一方向的旋转将紧固件的自攻螺纹部分穿过第一连杆构件中的孔。 紧固件旋转直到第一连杆构件与紧固件的头部齐平。 因此,紧固件将第一连杆构件可旋转地固定到第二连杆构件并且防止紧固件和第二连杆构件之间以及在第一连杆构件和第二连杆构件之间的横向自由移动运动。
    • 54. 发明授权
    • Pharmaceutical compounds
    • 药物化合物
    • US5700804A
    • 1997-12-23
    • US381932
    • 1995-04-11
    • Mark Anthony David CollinsMaria Ines Chicarelli-RobinsonJustin Stephen BryansStephen James BrocchiniChristopher John LathamJohn Richardson Shaw
    • Mark Anthony David CollinsMaria Ines Chicarelli-RobinsonJustin Stephen BryansStephen James BrocchiniChristopher John LathamJohn Richardson Shaw
    • A61K31/495A61P7/02A61P35/00C07D241/02C07D241/08
    • C07D241/02
    • Diketopiperazines of the formula: ##STR1## where each of R.sub.1 to R.sub.10, which may be the same or different, is independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by one or more halogen atoms, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, halogen, hydroxy, nitro, phenyl, -cyano, --CH.sub.2 OH, --CH.sub.2 COOH, --CO.sub.2 R.sup.11, --NHCOR.sup.11, --NHSO.sub.2 R.sup.13, --SO.sub.2 R.sup.13, --CON(R.sup.11 R.sup.12), --SOR.sup.13, --SO.sub.2 N(R.sup.11 R.sup.12), --N(R.sup.11 R.sup.12), and --O(CH.sub.2).sub.n N(R.sup.11 R.sup.12), --O(CH.sub.2).sub.n CO.sub.2 R.sup.11, --OCOR.sup.11, --CH.sub.2 OCOR.sup.11, --CH.sub.2 NHCOR.sup.11, --CH.sub.2 NHCOOR.sup.13, --CH.sub.2 SR.sup.11, --CH.sub.2 SCOR.sup.11, --CH.sub.2 S(O).sub.m R.sup.13 wherein m is 1 or 2, --CH.sub.2 NHCO(CH.sub.2).sub.n CO.sub.2 R.sup.11, --N(R.sup.11)COR.sup.12, --NHCOCF.sub.3, --NHCO(CH.sub.2).sub.n CO.sub.2 R.sup.11, --NHCO(CH.sub.2).sub.n OCOR.sup.11 and --NHCO(CH.sub.2).sub.n OR.sup.11 wherein n is 0 or is an integer of from 1 to 6, each of R.sup.11 and R.sup.12 is independently H or C.sub.1 -C.sub.6 alkyl and R.sup.13 is C.sub.1 -C.sub.6 alkyl; or any of R.sub.1 and R.sub.2, R.sub.2 and R.sub.3, R.sub.3 and R.sub.4 and R.sub.4 and R.sub.5, or R.sub.6 and R.sub.7, R.sub.7 and R.sub.8, R.sub.8 and R.sub.9 and R.sub.9 and R.sub.10, form together with the carbon atoms to which they are attached a benzene ring; and pharmaceutically acceptable salts and esters thereof are inhibitors of the plasminogen activator inhibitor.
    • PCT No.PCT / GB93 / 01734 Sec。 371日期1995年04月11日 102(e)日期1995年4月11日PCT提交1993年8月16日PCT公布。 第WO94 / 04512号公报 日期:1994年3月3日具有下式的下式的哌嗪基:不同的,独立地选自氢,未被取代或被一个或多个卤素原子取代的C 1 -C 6烷基,C 1 -C 6烷氧基,C 1 -C 6烷硫基 卤素,羟基,硝基,苯基, - 氰基,-CH 2 OH,-CH 2 COOH,-CO 2 R 11,-NHCOR 11,-NHSO 2 R 13,-SO 2 R 13,-CON(R 11 R 12),-SOR 13,-SO 2 N(R 11 R 12), - N(R 11 R 12) ,和-O(CH 2)n N(R 11 R 12),-O(CH 2)n CO 2 R 11,-OCOR 11,-CH 2 OCOR 11,-CH 2 NHCOR 11,-CH 2 NHCOOR 13,-CH 2 S R 11,-CH 2 SCOR 11,-CH 2 S(O)m R 13,其中m为1或2, -CH2NHCO(CH2)nCO2R11,-N(R11)COR12,-NHCOCF3,-NHCO(CH2)nCO2R11,-NHCO(CH2)nOCOR11和-NHCO(CH2)nOR11,其中n为0或为1至6的整数 R 11和R 12各自独立地为H或C 1 -C 6烷基,R 13为C 1 -C 6烷基; 或R 1和R 2中的任一个,R 2和R 3,R 3和R 4以及R 4和R 5或R 6,R 7,R 7和R 8,R 8和R 9以及R 9和R 10与它们所连接的碳原子一起形成苯环 ; 及其药学上可接受的盐和酯是纤溶酶原激活物抑制剂的抑制剂。